Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.19 USD | -3.92% | -3.33% | -35.56% |
May. 06 | Genenta Science S.p.A. Announces New Board Appointments | CI |
Apr. 08 | Genenta Science S.P.A. Announces Resignation of Board Members | CI |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 174.7 | 93.62 | 81.7 | 53.8 | - | - |
Enterprise Value (EV) 1 | 174.7 | 93.62 | 81.7 | 53.8 | 53.8 | 53.8 |
P/E ratio | -26.1 x | -10.9 x | -7.01 x | -3.5 x | -3.31 x | -3.29 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - |
EV / EBITDA | - | -8.48 x | - | -2.83 x | -1.78 x | -1.41 x |
EV / FCF | -25,074,510 x | - | - | - | - | - |
FCF Yield | -0% | - | - | - | - | - |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 18,120 | 18,217 | 18,217 | 18,290 | - | - |
Reference price 2 | 9.641 | 5.139 | 4.485 | 2.941 | 2.941 | 2.941 |
Announcement Date | 5/2/22 | 4/21/23 | 3/29/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - |
EBITDA 1 | - | - | -11.04 | - | -19 | -30.3 | -38.1 |
EBIT 1 | - | -5.687 | -11.04 | -11.73 | -19 | -24.33 | -30.07 |
Operating Margin | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -5.529 | -8.478 | -11.65 | -18.5 | -24.13 | -29.92 |
Net income 1 | -5.592 | -5.529 | -8.478 | -11.65 | -18.5 | -24.13 | -29.92 |
Net margin | - | - | - | - | - | - | - |
EPS 2 | -0.3800 | -0.3700 | -0.4700 | -0.6400 | -0.8400 | -0.8900 | -0.8950 |
Free Cash Flow | - | -6.967 | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 11/9/21 | 5/2/22 | 4/21/23 | 3/29/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 S1 | 2021 S2 | 2022 Q2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - |
EBITDA | - | - | - | -4.151 | -6.887 | -6.779 | - |
EBIT | - | -1.646 | - | - | -6.89 | - | -4.933 |
Operating Margin | - | - | - | - | - | - | - |
Earnings before Tax (EBT) | - | -1.481 | - | -2.112 | -6.365 | -6.759 | -4.886 |
Net income | -4.048 | -1.481 | - | -2.112 | -6.365 | -6.759 | -4.886 |
Net margin | - | - | - | - | - | - | - |
EPS | -0.2700 | -0.1000 | - | -0.1200 | -0.3500 | -0.3700 | -0.2700 |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 11/24/21 | 5/2/22 | 10/25/22 | 10/25/22 | 4/21/23 | 10/20/23 | 3/29/24 |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow | - | -6.97 | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex | - | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - |
Announcement Date | 11/9/21 | 5/2/22 | 4/21/23 | 3/29/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.56% | 58.34M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- GNTA Stock
- Financials Genenta Science S.p.A.